Research analysts at Wedbush started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “neutral” rating on the biopharmaceutical company’s stock.

ACOR has been the topic of a number of other research reports. BidaskClub lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 22nd. Zacks Investment Research upgraded Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $18.00 target price on shares of Acorda Therapeutics in a research report on Tuesday, May 7th. ValuEngine upgraded Acorda Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright set a $33.00 target price on Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 23rd. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Acorda Therapeutics currently has a consensus rating of “Hold” and an average price target of $22.56.

Shares of ACOR traded up $0.04 during mid-day trading on Wednesday, hitting $10.97. 600,158 shares of the company traded hands, compared to its average volume of 873,844. Acorda Therapeutics has a 1-year low of $9.58 and a 1-year high of $36.35. The company has a quick ratio of 3.97, a current ratio of 4.30 and a debt-to-equity ratio of 0.66. The company has a market cap of $526.54 million, a P/E ratio of 6.03 and a beta of 1.34.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.51. Acorda Therapeutics had a negative net margin of 1.40% and a positive return on equity of 9.34%. The firm had revenue of $44.14 million for the quarter, compared to the consensus estimate of $35.14 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s revenue for the quarter was down 58.4% compared to the same quarter last year. On average, research analysts anticipate that Acorda Therapeutics will post -3.92 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its position in Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,062 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Acorda Therapeutics in the 4th quarter worth approximately $44,000. Financial Gravity Wealth Inc. purchased a new stake in Acorda Therapeutics in the 1st quarter worth approximately $44,000. NumerixS Investment Technologies Inc purchased a new stake in Acorda Therapeutics in the 4th quarter worth approximately $77,000. Finally, Piedmont Investment Advisors Inc. purchased a new stake in Acorda Therapeutics in the 1st quarter worth approximately $134,000.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

See Also: What is intrinsic value?

The Fly

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.